Table 4.
Agreement between multiparametric magnetic resonance imaging and pathological staging
| Outcome | Patients, n (%) |
p value | ||
|---|---|---|---|---|
| PI-QUAL 1–2 (n = 40) |
PI-QUAL 3 (n = 57) |
PI-QUAL 4–5 (n = 254) |
||
| Agreement | 25 (62.5) | 45 (79.0) | 180 (70.9) | 0.206 |
| Pathological upstaging a | 14 (35) | 10 (17.5) | 49 (19.3) | 0.06 |
| Pathological downstaging b | 1 (2.5) | 2 (3.5) | 25 (9.8) | 0.111 |
PI-QUAL = Prostate Imaging Quality score (nondiagnostic, PI-QUAL 1–2; sufficient, PI-QUAL 3; optimal, PI-QUAL 4–5).
a
Pathological upstaging is locally advanced disease on pathology for the prostatectomy specimen (pT3a or pT3b) for cancer clinically diagnosed as mrT2 stage.
b
Pathological downstaging is pT2 stage on pathology for the prostatectomy specimen for cancer clinically diagnosed as locally advanced disease on multiparametric magnetic resonance imaging (mrT3a or mrT3b).